Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Saved in:
| Title: | Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. |
|---|---|
| Authors: | Zamulko O; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio., Karivedu V; Division of Hematology/Oncology, Duke University Medical Center, Durham, North Carolina., Riaz MK; St. Elizabeth Healthcare, Edgewood, Kentucky., Monroe I; University of Cincinnati Cancer Center, Cincinnati, Ohio., Romano A; University of Cincinnati Cancer Center, Cincinnati, Ohio., Mulanda R; University of Cincinnati Cancer Center, Cincinnati, Ohio., Kurtzweil N; University of Cincinnati Cancer Center, Cincinnati, Ohio., Forsythe A; University of Cincinnati Cancer Center, Cincinnati, Ohio., Allen CL; University of Cincinnati Cancer Center, Cincinnati, Ohio., Harun N; Cytel, Cincinnati, Ohio., Pan J; Biostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio.; Cancer Data Science Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.; Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio., Rai S; Biostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio.; Cancer Data Science Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.; Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio., El-Gamal D; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio., Wise-Draper TM; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio. |
| Source: | Cancer research communications [Cancer Res Commun] 2025 Jun 01; Vol. 5 (6), pp. 939-944. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40377969 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Zamulko+O%22">Zamulko O</searchLink>; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Karivedu+V%22">Karivedu V</searchLink>; Division of Hematology/Oncology, Duke University Medical Center, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Riaz+MK%22">Riaz MK</searchLink>; St. Elizabeth Healthcare, Edgewood, Kentucky.<br /><searchLink fieldCode="AU" term="%22Monroe+I%22">Monroe I</searchLink>; University of Cincinnati Cancer Center, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Romano+A%22">Romano A</searchLink>; University of Cincinnati Cancer Center, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Mulanda+R%22">Mulanda R</searchLink>; University of Cincinnati Cancer Center, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Kurtzweil+N%22">Kurtzweil N</searchLink>; University of Cincinnati Cancer Center, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Forsythe+A%22">Forsythe A</searchLink>; University of Cincinnati Cancer Center, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Allen+CL%22">Allen CL</searchLink>; University of Cincinnati Cancer Center, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Harun+N%22">Harun N</searchLink>; Cytel, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Pan+J%22">Pan J</searchLink>; Biostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio.; Cancer Data Science Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.; Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Rai+S%22">Rai S</searchLink>; Biostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio.; Cancer Data Science Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.; Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22El-Gamal+D%22">El-Gamal D</searchLink>; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.<br /><searchLink fieldCode="AU" term="%22Wise-Draper+TM%22">Wise-Draper TM</searchLink>; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229918281580506676%22">Cancer research communications</searchLink> [Cancer Res Commun] 2025 Jun 01; Vol. 5 (6), pp. 939-944. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918281580506676 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2767-9764 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2227679764%22">27679764 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Res Commun <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40377969 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1158/2767-9764.CRC-25-0192 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 939 Titles: – TitleFull: Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zamulko O – PersonEntity: Name: NameFull: Karivedu V – PersonEntity: Name: NameFull: Riaz MK – PersonEntity: Name: NameFull: Monroe I – PersonEntity: Name: NameFull: Romano A – PersonEntity: Name: NameFull: Mulanda R – PersonEntity: Name: NameFull: Kurtzweil N – PersonEntity: Name: NameFull: Forsythe A – PersonEntity: Name: NameFull: Allen CL – PersonEntity: Name: NameFull: Harun N – PersonEntity: Name: NameFull: Pan J – PersonEntity: Name: NameFull: Rai S – PersonEntity: Name: NameFull: El-Gamal D – PersonEntity: Name: NameFull: Wise-Draper TM IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2025 Jun 01 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2767-9764 Numbering: – Type: volume Value: 5 – Type: issue Value: 6 Titles: – TitleFull: Cancer research communications Type: main |
| ResultId | 1 |
